Table 3.
Multivariable Analysis of OS and PFS for All Patients with Known CDKN2A/B Deletion Status (n = 150)
| Characteristics | OS | P Value | PFS | P Value |
|---|---|---|---|---|
| Age at diagnosis | 1.00 (0.98–1.02) | .90 | 1.00 (0.98–1.02) | .85 |
| KPS | 0.98 (0.96–0.995) | .009 | 0.98 (0.96–0.99) | .001 |
| mGBM | 0.54 (0.25–1.18) | .12 | 0.46 (0.23–0.92) | .03 |
| Extent of resection | ||||
| GTR | Ref | |||
| STR | 1.88 (1.08–3.27) | .03 | 2.23 (1.38–3.61) | .001 |
| Biopsy | 3.00 (1.79–5.03) | <.001 | 3.93 (2.38–6.50) | <.001 |
| Unmethylated MGMT | 1.82 (1.12–2.96) | .02 | 2.87 (1.80–4.58) | <.001 |
| HFRT | 2.40 (1.23–4.67) | .01 | 1.39 (0.76–2.56) | .29 |
| No TMZ chemotherapy | 1.28 (0.66–2.47) | .46 | 1.16 (0.63–2.15) | .64 |
| CDKN2A/B deletion by NGS | 1.57 (1.003–2.46) | .048 | 1.57 (1.04–2.36) | .03 |
FISH, fluorescence in situ hybridization; GTR, gross-total/near-total resection; HFRT, short-course hypofractionated radiation therapy; hGBM, histological GBM; mGBM, molecular glioblastoma; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; STR, subtotal resection; TMZ, temozolomide.